ERBB2 and neoplasm: Similar to our MBC cohort, we selected women diagnosed with invasive intraductal carcinoma (95.4%), HR-positive and HER2-negative tumours (92.7%) and screened the whole coding region of the 14 previously identified genes for any PVs/LPVs.